Microencapsulation of ketorolac tromethamine by means of a coacervation phase separation technique induced by the addition of non-solvent

Genc L., Demirel M., Guler E., Hegazy N.

JOURNAL OF MICROENCAPSULATION, vol.15, no.1, pp.45-53, 1998 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 15 Issue: 1
  • Publication Date: 1998
  • Doi Number: 10.3109/02652049809006834
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.45-53
  • Keywords: ketorolac tromethamine, microencapsulation, coacervation-phase separation, Eudragit S100, non-solvent, MICROCAPSULES, PHARMACOKINETICS, POLYMER, HUMANS
  • Anadolu University Affiliated: No


Ketorolac tromethamine (KT) is a non-steroidal drug with potent analgesic and anti-inflammatory activity and is absorbed rapidly (T-max (1.0h) with an efficiency >87% following oral and intramuscular administration. The plasma half-life of ketorolac ranges from 1.1 to 6.0 h. Its oral bioavailability is estimated to be 80%. Ketorolac has been found 36 times more potent than phenylbutazone, approximately twice as potent as indomethacin, and three times more potent than naproxen in suppressing carrageenan-induced paw oedema in rat. In this study, microcapsules of KT were prepared by means of coaceruation-phase separation technique induced by the addition of non-solvent, and release rates from microcapsules were studied. Eudragit S100 was used as the coating material. Coacervation was achieved by the addition of cyclohexane at 2 ml/min at 25 degrees C and 1:4 solvent:non-solvent ratio was used. The microcapsules were washed with cyclohexane to harden the wall and dried at room temperature. Microcapsules with core:wall ratio of 1:1 and 1:2 were prepared and the particles obtained by sieving with an average diameter of 177-500 mu m were used. The yield was calculated and the release properties of KT were investigated by USP XXII paddle method and using UV spectrophotometry at 318 and 323 nm.